SCHEMBL7357698

SCHEMBL7357698

NC(=O)C[C@H](NC(=O)c1ccc2ccccc2n1)C(N)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
GAA P10253 2/20 0.60
MAPT P10636 1/20 0.60
HDAC8 Q9BY41 1/20 0.54
KDM4C Q9H3R0 1/20 0.51
RAB9A P51151 3/20 0.50
NFKB1 P19838 2/20 0.50
NFKB2 Q00653 2/20 0.50
RELA Q04206 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CTSD P07339 1/20 0.50
SCN9A Q15858 1/20 0.49
HPGD P15428 1/20 0.48
HDAC1 Q13547 2/20 0.47
MGAM O43451 1/20 0.46
NPC1 O15118 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TP53 P04637 1/20 0.46
TSHR P16473 1/20 0.46
MCHR1 Q99705 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6976264 1.00 ALDH1A1 (0.60) ALDH1A1GAAMAPTHDAC8KDM4C
SCHEMBL30051464 1.00 ALDH1A1 (0.60) ALDH1A1GAAMAPTHDAC8KDM4C
SCHEMBL9272265 1.00 ALDH1A1 (0.60) ALDH1A1GAAMAPTHDAC8KDM4C
SCHEMBL4891798 0.91 ALDH1A1 (0.58) ALDH1A1GAAMAPTHDAC8KDM4C
SCHEMBL561849 0.91 ALDH1A1 (0.58) ALDH1A1GAAMAPTHDAC8KDM4C
SCHEMBL6444839 0.91 ALDH1A1 (0.58) ALDH1A1GAAMAPTHDAC8KDM4C
Hydrochloric Acid SCHEMBL4862500 0.90 ALDH1A1 (0.57) ALDH1A1GAAMAPTHDAC8KDM4C
SCHEMBL8667829 0.88 ALDH1A1 (0.56) ALDH1A1GAAMAPTHDAC8KDM4C
SCHEMBL27559596 0.86 ALDH1A1 (0.60) ALDH1A1GAAMAPTHDAC8KDM4C
SCHEMBL6445106 0.83 ALDH1A1 (0.50) ALDH1A1GAAMAPTHDAC8KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021201-A1 Protease inhibitor conjugates and antibodies useful in immunoassay SIGLER GERALD F 2008-01-24 US disclosed
US-7193065-B2 Protease inhibitor conjugates and antibodies useful in immunoassay ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2007-03-20 US disclosed
EP-1005448-A2 NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS Du Pont Pharmaceuticals Company (US) 2000-06-07 EP disclosed
WO-1999009000-A2 NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS DU PONT PHARMACEUTICALS COMPANY (US) 1999-02-25 WO disclosed
WO-1992020344-A1 ANTIVIRAL COMBINATIONS CONTAINING NUCLEOSIDE ANALOGS GLAXO GROUP LIMITED (GB) 1992-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021201-A1 Protease inhibitor conjugates and antibodies useful in immunoassay SERPINB1, HPN, SPR ALDH1A1 547/4885GAA 394/4885MAPT 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.